Healthcare -
Biotechnology - NASDAQ - US
$ 11.035
-2.1 %
$ 286 M
Market Cap
1.75
P/E
1. INTRINSIC VALUE
Balance Sheet
Cartesian Therapeutics, Inc.
| Current Assets | 217 M |
| Cash & Short-Term Investments | 213 M |
| Receivables | 872 K |
| Other Current Assets | 3.14 M |
| Non-Current Assets | 218 M |
| Long-Term Investments | 2 M |
| PP&E | 15.4 M |
| Other Non-Current Assets | 201 M |
| Current Liabilities | 23 M |
| Accounts Payable | 288 K |
| Short-Term Debt | 2.85 M |
| Other Current Liabilities | 19.8 M |
| Non-Current Liabilities | 419 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 419 M |
EFFICIENCY
Earnings Waterfall
Cartesian Therapeutics, Inc.
| Revenue | 38.9 M |
| Cost Of Revenue | 0 |
| Gross Profit | 38.9 M |
| Operating Expenses | 82.8 M |
| Operating Income | -43.9 M |
| Other Expenses | 33.5 M |
| Net Income | -77.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cartesian Therapeutics, Inc.
| Net Income | -77.4 M |
| Depreciation & Amortization | 1.15 M |
| Capital Expenditures | -9.09 M |
| Stock-Based Compensation | 6.58 M |
| Change in Working Capital | -5.79 M |
| Others | 40.7 M |
| Free Cash Flow | -32.8 M |
Wall Street Analysts Price Targets
Cartesian Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for RNAC of $43.2 , with forecasts ranging from
a
low of
$40 to a high of $45 .
RNAC Lowest Price Target
Wall Street Target
40 USD
262.48%
RNAC Average Price Target
Wall Street Target
43.2 USD
291.48%
RNAC Highest Price Target
Wall Street Target
45 USD
307.79%
4. DIVIDEND
ANALYSIS
RNAC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cartesian Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
610 K USD 6
6-9 MONTHS
4.21 M USD 3
9-12 MONTHS
0 USD 0
Bought
2.38 M USD 1
0-3 MONTHS
1.85 M USD 1
3-6 MONTHS
11.7 M USD 1
6-9 MONTHS
197 K USD 2
9-12 MONTHS
7. News
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
globenewswire.com
- 2 weeks ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).
globenewswire.com
- 2 weeks ago
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial
globenewswire.com
- 1 month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
globenewswire.com
- 1 month ago
Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12
globenewswire.com
- 2 months ago
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company's common stock with an exercise price of $12.49, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on April 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on April 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
globenewswire.com
- 2 months ago
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET.
globenewswire.com
- 2 months ago
Substantial Insider Buying: American Express, Asana, and More
Retirement can be daunting, but it doesn't need to be. Imagine having an expert in your corner to help you with your financial goals.
247wallst.com
- 2 months ago
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company's common stock with an exercise price of $17.50, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on March 3, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on March 3, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.
globenewswire.com
- 3 months ago
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March:
globenewswire.com
- 4 months ago
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company's common stock with an exercise price of $19.89, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on February 3, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on February 3, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
globenewswire.com
- 4 months ago
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company's planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG).
globenewswire.com
- 4 months ago
8. Profile
Summary
Cartesian Therapeutics, Inc. RNAC
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 286 M
Dividend Yield
0.00%
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Contact
65 Grove Street, Watertown, MA, 02472
https://selectabio.com
IPO
Date
June 22, 2016
Employees
66
Officers
Dr. Metin Kurtoglu M.D., Ph.D.
Consultant
Mr. Blaine T. Davis
Chief Financial Officer
Dr. Milos Miljkovic M.D., Ph.D.
Chief Medical Officer
Dr. Chris Jewell Ph.D.
Chief Scientific Officer
Mr. Matthew Bartholomae J.D.
General Counsel & Secretary
Dr. Carsten Brunn Ph.D.
President, Chief Executive Officer & Director
Dr. Emily English Ph.D.
Chief Operating Officer